{"id":"sequential-lenvatinib","safety":{"commonSideEffects":[{"rate":"50-70%","effect":"Hypertension"},{"rate":"30-50%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Weight loss"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting these receptors, lenvatinib reduces angiogenesis and tumor growth. This mechanism is particularly effective in treating various types of cancer.","oneSentence":"Sequential lenvatinib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR) and fibroblast growth factor receptors (FGFR).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:56.638Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic renal cell carcinoma"},{"name":"Locally advanced or metastatic radiodermatitis"}]},"trialDetails":[{"nctId":"NCT05532319","phase":"PHASE2","title":"HAIC Sequential TAE Combined With Lenvatinib and Tislelizumab in Unresectable HCC","status":"COMPLETED","sponsor":"Guangxi Medical University","startDate":"2022-11-10","conditions":"Liver Cancer","enrollment":64},{"nctId":"NCT07052448","phase":"","title":"The Efficacy of Sequential RT After Triple Therapy for uHCC","status":"ENROLLING_BY_INVITATION","sponsor":"Fujian Provincial Hospital","startDate":"2020-11-01","conditions":"Hepatocellular Carcinoma","enrollment":35},{"nctId":"NCT05188118","phase":"EARLY_PHASE1","title":"Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2023-02-15","conditions":"Renal Cell Carcinoma","enrollment":20},{"nctId":"NCT06061276","phase":"NA","title":"bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-05-20","conditions":"Liver Diseases, Hepatocellular Carcinoma, Immunotherapy","enrollment":40},{"nctId":"NCT06041477","phase":"PHASE3","title":"Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-10-31","conditions":"Hepatocellular Carcinoma, Chemotherapy Effect, Chemotherapeutic Toxicity","enrollment":540},{"nctId":"NCT06561399","phase":"","title":"Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)","status":"RECRUITING","sponsor":"Fujian Provincial Hospital","startDate":"2024-08-15","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":28},{"nctId":"NCT06070636","phase":"NA","title":"bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-05-20","conditions":"Liver Diseases, Hepatocellular Carcinoma, Immunotherapy","enrollment":30},{"nctId":"NCT05220020","phase":"PHASE3","title":"TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2022-05-18","conditions":"Hepatocellular Carcinoma","enrollment":299},{"nctId":"NCT05322187","phase":"PHASE2, PHASE3","title":"Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2022-04-10","conditions":"Transitional Cell Tumor, Hepatoblastoma, Liver Cancer","enrollment":15},{"nctId":"NCT04714697","phase":"PHASE2","title":"Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2021-03-01","conditions":"Renal Cell Cancer","enrollment":201}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":148,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sequential targeted therapy"],"phase":"phase_3","status":"active","brandName":"Sequential Lenvatinib","genericName":"Sequential Lenvatinib","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sequential lenvatinib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR) and fibroblast growth factor receptors (FGFR). Used for Metastatic renal cell carcinoma, Locally advanced or metastatic radiodermatitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}